Piramal Pharma

Piramal Pharma has received a Form 483 from the United States Food and Drug Administration following an inspection of one of its manufacturing facilities. The regulatory document outlines specific observations related to procedural or compliance gaps that require corrective action. While a Form 483 does not constitute a final regulatory action or import restriction, it signals areas where the company must strengthen quality systems and documentation practices. Piramal Pharma stated it will respond within the stipulated timeline and implement necessary remediation measures.

Piramal Pharma Ltd. reported a consolidated net loss of Rs 136 crore for the third quarter, as inventory-related challenges and cost pressures weighed on financial performance. Despite steady operational activity across its contract development and manufacturing services and consumer healthcare segments, elevated inventory levels and associated expenses eroded profitability. The results prompted a cautious response from investors, highlighting concerns over near-term earnings visibility.